WO2008087017A2 - Neue kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel - Google Patents
Neue kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel Download PDFInfo
- Publication number
- WO2008087017A2 WO2008087017A2 PCT/EP2008/000285 EP2008000285W WO2008087017A2 WO 2008087017 A2 WO2008087017 A2 WO 2008087017A2 EP 2008000285 W EP2008000285 W EP 2008000285W WO 2008087017 A2 WO2008087017 A2 WO 2008087017A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- coch
- cascade
- ethoxy
- optionally
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000008177 pharmaceutical agent Substances 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 40
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- 150000002500 ions Chemical class 0.000 claims abstract description 19
- 230000027455 binding Effects 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 150000001768 cations Chemical class 0.000 claims abstract description 13
- 150000007530 organic bases Chemical class 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- -1 aminopropyl Chemical group 0.000 claims description 62
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 239000008139 complexing agent Substances 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 150000001408 amides Chemical class 0.000 claims description 19
- 150000001412 amines Chemical class 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 16
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 4
- FKUUAMCSPLBGEE-UHFFFAOYSA-N 3,4,5-tris(2-aminoethoxy)aniline Chemical compound NCCOC1=CC(N)=CC(OCCN)=C1OCCN FKUUAMCSPLBGEE-UHFFFAOYSA-N 0.000 claims description 3
- XADBDUHWDPECBO-UHFFFAOYSA-N 3,4,5-tris(2-aminoethoxy)benzamide Chemical compound NCCOC1=CC(C(N)=O)=CC(OCCN)=C1OCCN XADBDUHWDPECBO-UHFFFAOYSA-N 0.000 claims description 3
- JJSMLVBHRDPIJL-UHFFFAOYSA-N 3,4,5-tris(3-aminopropoxy)aniline Chemical compound NCCCOC1=CC(N)=CC(OCCCN)=C1OCCCN JJSMLVBHRDPIJL-UHFFFAOYSA-N 0.000 claims description 3
- UCCKOBVJXCXHRD-UHFFFAOYSA-N 3,4,5-tris(3-aminopropoxy)benzamide Chemical compound NCCCOC1=CC(C(N)=O)=CC(OCCCN)=C1OCCCN UCCKOBVJXCXHRD-UHFFFAOYSA-N 0.000 claims description 3
- QTNUDOMJXXAGOW-UHFFFAOYSA-N 3,5-bis(2-aminoethoxy)aniline Chemical compound NCCOC1=CC(N)=CC(OCCN)=C1 QTNUDOMJXXAGOW-UHFFFAOYSA-N 0.000 claims description 3
- IOYSYBCPMGUQAS-UHFFFAOYSA-N 3,5-bis(2-aminoethoxy)benzamide Chemical compound NCCOC1=CC(OCCN)=CC(C(N)=O)=C1 IOYSYBCPMGUQAS-UHFFFAOYSA-N 0.000 claims description 3
- ZASLJBCFQFNYQP-UHFFFAOYSA-N 3,5-bis(3-aminopropoxy)aniline Chemical compound NCCCOC1=CC(N)=CC(OCCCN)=C1 ZASLJBCFQFNYQP-UHFFFAOYSA-N 0.000 claims description 3
- UAYTZLSRAXKKJC-UHFFFAOYSA-N 3,5-bis(3-aminopropoxy)benzamide Chemical compound NCCCOC1=CC(OCCCN)=CC(C(N)=O)=C1 UAYTZLSRAXKKJC-UHFFFAOYSA-N 0.000 claims description 3
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 3
- HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims description 3
- UGDSCHVVUPHIFM-UHFFFAOYSA-N 1,1,1-tris(aminomethyl)ethane Chemical compound NCC(C)(CN)CN UGDSCHVVUPHIFM-UHFFFAOYSA-N 0.000 claims description 2
- UUEQNWFHJLYOPW-UHFFFAOYSA-N 1,4,7,10,13,16,19,22,25,28-decazacyclotriacontane Chemical compound C1CNCCNCCNCCNCCNCCNCCNCCNCCNCCN1 UUEQNWFHJLYOPW-UHFFFAOYSA-N 0.000 claims description 2
- RVJABZUDCPZPPM-UHFFFAOYSA-N 1,4,7,10,13,16-hexazacyclooctadecane Chemical compound C1CNCCNCCNCCNCCNCCN1 RVJABZUDCPZPPM-UHFFFAOYSA-N 0.000 claims description 2
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims description 2
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 claims description 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 2
- VVJIVFKAROPUOS-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diamine Chemical compound NCC(CN)(CN)CN VVJIVFKAROPUOS-UHFFFAOYSA-N 0.000 claims description 2
- FCIGUPDFRXUJSZ-UHFFFAOYSA-N 4-(3-aminopropyl)-4-nitroheptane-1,7-diamine Chemical compound NCCCC(CCCN)(CCCN)[N+]([O-])=O FCIGUPDFRXUJSZ-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- IDWDEHYPSCTKFU-UHFFFAOYSA-N [3,5-bis(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC(CN)=CC(CN)=C1 IDWDEHYPSCTKFU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 2
- ZMUADARPXLFDHP-UHFFFAOYSA-N nitrocarbamic acid Chemical group OC(=O)N[N+]([O-])=O ZMUADARPXLFDHP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 claims description 2
- OERRZAJTKPMGBB-BYPYZUCNSA-N (2s)-2,5-diaminopentanamide Chemical compound NCCC[C@H](N)C(N)=O OERRZAJTKPMGBB-BYPYZUCNSA-N 0.000 claims 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 claims 1
- KDCBVVQAMMXRFB-UHFFFAOYSA-N 1,4,7,10,13-pentazacyclopentadecane Chemical compound C1CNCCNCCNCCNCCN1 KDCBVVQAMMXRFB-UHFFFAOYSA-N 0.000 claims 1
- LDOMKUVUXZRECL-UHFFFAOYSA-N 2-aminobenzene-1,3-dicarboxylic acid Chemical compound NC1=C(C(O)=O)C=CC=C1C(O)=O LDOMKUVUXZRECL-UHFFFAOYSA-N 0.000 claims 1
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 1
- WXWQVSOHWXJBDF-UHFFFAOYSA-N benzene-1,3,5-tricarboxamide Chemical compound NC(=O)C1=CC(C(N)=O)=CC(C(N)=O)=C1 WXWQVSOHWXJBDF-UHFFFAOYSA-N 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 14
- 150000007529 inorganic bases Chemical class 0.000 abstract description 9
- 229910052700 potassium Inorganic materials 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 93
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 59
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 41
- 238000000921 elemental analysis Methods 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 239000000047 product Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 229960004132 diethyl ether Drugs 0.000 description 31
- 239000002872 contrast media Substances 0.000 description 28
- 239000000126 substance Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 25
- 238000007792 addition Methods 0.000 description 25
- 238000012512 characterization method Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- JMQURLDQTNONQC-UHFFFAOYSA-N benzyl N-[1-[[1-(2-aminoethylamino)-6-[2,6-bis(phenylmethoxycarbonylamino)hexanoylamino]-1-oxohexan-2-yl]amino]-1-oxo-6-(phenylmethoxycarbonylamino)hexan-2-yl]carbamate Chemical compound C(C1=CC=CC=C1)OC(=O)NC(C(=O)NC(C(=O)NCCN)CCCCNC(C(CCCCNC(=O)OCC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1)=O)CCCCNC(=O)OCC1=CC=CC=C1 JMQURLDQTNONQC-UHFFFAOYSA-N 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 14
- 229910052688 Gadolinium Inorganic materials 0.000 description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 13
- 239000012043 crude product Substances 0.000 description 12
- 239000012362 glacial acetic acid Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 239000012465 retentate Substances 0.000 description 11
- PUXJRFSROJSYDG-UHFFFAOYSA-N 2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetic acid Chemical compound CC1=CC(C)=CC(C)=C1C1=CC(C)=C(OCC(O)=O)C=C1C PUXJRFSROJSYDG-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 229920001429 chelating resin Polymers 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 238000011065 in-situ storage Methods 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 0 *N(CCN(CCN(CC1)[U])[U])CCN1[U] Chemical compound *N(CCN(CCN(CC1)[U])[U])CCN1[U] 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 239000000412 dendrimer Substances 0.000 description 8
- 229920000736 dendritic polymer Polymers 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 238000005917 acylation reaction Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- PATVTXAXTZIAMN-UHFFFAOYSA-N n-(2-aminoethyl)-4-phenylbenzamide Chemical compound C1=CC(C(=O)NCCN)=CC=C1C1=CC=CC=C1 PATVTXAXTZIAMN-UHFFFAOYSA-N 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 4
- 150000002540 isothiocyanates Chemical class 0.000 description 4
- 229960003104 ornithine Drugs 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- WTNMWCJVEAIMLV-UHFFFAOYSA-N 2-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetic acid Chemical compound OC(=O)CNC(=O)C(C)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WTNMWCJVEAIMLV-UHFFFAOYSA-N 0.000 description 3
- AFHQTYZHKNSRKR-UHFFFAOYSA-N 2-[[2-cyclohexyl-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1C(C(=O)NCC(=O)O)C1CCCCC1 AFHQTYZHKNSRKR-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- DEKPYXUDJRABNK-UHFFFAOYSA-N dimethyl 5-aminobenzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(N)=CC(C(=O)OC)=C1 DEKPYXUDJRABNK-UHFFFAOYSA-N 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- UWRZZIJUPTZKBP-UHFFFAOYSA-N 11-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]undecanoic acid Chemical compound CC1=CC(C)=CC(C)=C1C1=CC(C)=C(OCC(=O)NCCCCCCCCCCC(O)=O)C=C1C UWRZZIJUPTZKBP-UHFFFAOYSA-N 0.000 description 2
- XJNPVJPEKCXUTR-UHFFFAOYSA-N 12-[[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]-hydroxyphosphoryl]oxydodecanoic acid Chemical class CC1=CC(C)=CC(C)=C1C1=CC(C)=C(OP(O)(=O)OCCCCCCCCCCCC(O)=O)C=C1C XJNPVJPEKCXUTR-UHFFFAOYSA-N 0.000 description 2
- BJVVRKPLSDLMGT-UHFFFAOYSA-N 2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenol Chemical compound CC1=CC(C)=CC(C)=C1C1=CC(C)=C(O)C=C1C BJVVRKPLSDLMGT-UHFFFAOYSA-N 0.000 description 2
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 229940075613 gadolinium oxide Drugs 0.000 description 2
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 2
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- KGAPXJXHUGPJTH-ZEQRLZLVSA-N (2s)-6-amino-2-[[(2s)-2,6-bis(phenylmethoxycarbonylamino)hexanoyl]amino]hexanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)OCC=1C=CC=CC=1)CCCNC(=O)OCC1=CC=CC=C1 KGAPXJXHUGPJTH-ZEQRLZLVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- PIYNUZCGMLCXKJ-UHFFFAOYSA-N 1,4-dioxane-2,6-dione Chemical compound O=C1COCC(=O)O1 PIYNUZCGMLCXKJ-UHFFFAOYSA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VPGRCBYJFQCYAL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-5-[(4-phenylbenzoyl)amino]benzene-1,3-dicarboxylic acid Chemical compound C(C)(C)(C)OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCC1=C(C(=O)O)C=C(C=C1C(=O)O)NC(=O)C1=CC=C(C=C1)C1=CC=CC=C1 VPGRCBYJFQCYAL-UHFFFAOYSA-N 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid;gadolinium(3+) Chemical compound [Gd+3].CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-N 0.000 description 1
- PYSDGWHRTNYGOK-UHFFFAOYSA-N 2-amino-7-oxo-7-phenylmethoxy-2-phenylmethoxycarbonylheptanoic acid Chemical compound C=1C=CC=CC=1COC(=O)C(N)(C(O)=O)CCCCC(=O)OCC1=CC=CC=C1 PYSDGWHRTNYGOK-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- RRDPWAPIJGSANI-UHFFFAOYSA-N 2-cyclohexyl-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1CCCCC1 RRDPWAPIJGSANI-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 1
- FIKSVNNJPIFKOC-UHFFFAOYSA-N 4-[2-[4-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]phenyl]ethynyl]benzoic acid Chemical compound CC1=CC(C)=CC(C)=C1C(C(=C1)C)=CC(C)=C1OCC(=O)NC1=CC=C(C#CC=2C=CC(=CC=2)C(O)=O)C=C1 FIKSVNNJPIFKOC-UHFFFAOYSA-N 0.000 description 1
- RFAXNKKOQUYDKE-UHFFFAOYSA-N 4-iodo-2,5-dimethylphenol Chemical compound CC1=CC(I)=C(C)C=C1O RFAXNKKOQUYDKE-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- GHICCUXQJBDNRN-UHFFFAOYSA-N 4-iodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C=C1 GHICCUXQJBDNRN-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- JGGAFASHZOHWRQ-UHFFFAOYSA-N 5-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]benzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C)=CC(C)=C1C(C(=C1)C)=CC(C)=C1OCC(=O)NC1=CC(C(O)=O)=CC(C(O)=O)=C1 JGGAFASHZOHWRQ-UHFFFAOYSA-N 0.000 description 1
- CUGDYSSBTWBKII-UHFFFAOYSA-N 6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)CC(O)C(O)C(O)C(O)CO CUGDYSSBTWBKII-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NULSITDJPAFFFI-UHFFFAOYSA-N C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC3=CC(=C(C(=C3)C(=O)O)CCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)O)C(=O)O Chemical compound C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC3=CC(=C(C(=C3)C(=O)O)CCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)O)C(=O)O NULSITDJPAFFFI-UHFFFAOYSA-N 0.000 description 1
- HGBBMHISVKHICR-UHFFFAOYSA-N CC1=CC(=C(C(=C1)C)C2=C(C=C(C(=C2)C)OCC(=O)NC3=C(C=C(C=C3)[Si](C)(C)C)C#C)C)C Chemical compound CC1=CC(=C(C(=C1)C)C2=C(C=C(C(=C2)C)OCC(=O)NC3=C(C=C(C=C3)[Si](C)(C)C)C#C)C)C HGBBMHISVKHICR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- UYILZWUWPBSANM-UHFFFAOYSA-N Nc1nc(N([U])[U])nc(N([U])[U])n1 Chemical compound Nc1nc(N([U])[U])nc(N([U])[U])n1 UYILZWUWPBSANM-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- YQVISGXICTVSDQ-UHFFFAOYSA-O [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C Chemical compound [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C YQVISGXICTVSDQ-UHFFFAOYSA-O 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HDCOASUQLNMOPF-UHFFFAOYSA-N acetamide;2-aminoacetic acid Chemical compound CC(N)=O.NCC(O)=O HDCOASUQLNMOPF-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000001636 atomic emission spectroscopy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- FZBHYTHUYUHHBT-UHFFFAOYSA-N benzyl 2-[cyclohexyl-(2-hydroxyacetyl)amino]acetate Chemical compound C1CCCCC1N(C(=O)CO)CC(=O)OCC1=CC=CC=C1 FZBHYTHUYUHHBT-UHFFFAOYSA-N 0.000 description 1
- XWUKELGLHUNISU-UHFFFAOYSA-N benzyl N-[1-[[1-[2-[2-[2,6-bis[2,6-bis(phenylmethoxycarbonylamino)hexanoylamino]hexanoylamino]ethyl-[4-[2-[4-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]phenyl]ethynyl]benzoyl]amino]ethylamino]-6-[2,6-bis(phenylmethoxycarbonylamino)hexanoylamino]-1-oxohexan-2-yl]amino]-1-oxo-6-(phenylmethoxycarbonylamino)hexan-2-yl]carbamate Chemical compound CC1=CC(C)=CC(C)=C1C(C(=C1)C)=CC(C)=C1OCC(=O)NC1=CC=C(C#CC=2C=CC(=CC=2)C(=O)N(CCNC(=O)C(CCCCNC(=O)C(CCCCNC(=O)OCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)NC(=O)C(CCCCNC(=O)OCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)CCNC(=O)C(CCCCNC(=O)C(CCCCNC(=O)OCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)NC(=O)C(CCCCNC(=O)OCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)C=C1 XWUKELGLHUNISU-UHFFFAOYSA-N 0.000 description 1
- PFXWAZGPFWJKBF-UHFFFAOYSA-N benzyl aziridine-1-carboxylate Chemical compound C1CN1C(=O)OCC1=CC=CC=C1 PFXWAZGPFWJKBF-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- WJKJXKRHMUXQSL-UHFFFAOYSA-N benzyl glycinate 4-methylbenzenesulfonate salt Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)OCC1=CC=CC=C1 WJKJXKRHMUXQSL-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FAWMTAYSZSOSBS-UHFFFAOYSA-N dimethyl 5-[(4-phenylbenzoyl)amino]benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(C(=O)OC)=CC(NC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 FAWMTAYSZSOSBS-UHFFFAOYSA-N 0.000 description 1
- PXHSGPKGNKSUQO-UHFFFAOYSA-N dimethyl 5-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(C(=O)OC)=CC(NC(=O)COC=2C(=CC(=C(C)C=2)C=2C(=CC(C)=CC=2C)C)C)=C1 PXHSGPKGNKSUQO-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000012477 high molecular weight ligand Substances 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- NYUQFVJVODUGOW-UHFFFAOYSA-L magnesium;1,3,5-trimethylbenzene;dibromide Chemical compound [Mg+2].[Br-].[Br-].CC1=CC(C)=CC(C)=C1 NYUQFVJVODUGOW-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QBPCICJOGIJKGU-UHFFFAOYSA-N methyl 11-[[2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetyl]amino]undecanoate Chemical compound C1=C(C)C(OCC(=O)NCCCCCCCCCCC(=O)OC)=CC(C)=C1C1=C(C)C=C(C)C=C1C QBPCICJOGIJKGU-UHFFFAOYSA-N 0.000 description 1
- KFYATKQGODTGCP-UHFFFAOYSA-N methyl 12-[[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]-[(2-methylpropan-2-yl)oxy]phosphoryl]oxydodecanoate Chemical compound C1=C(C)C(OP(=O)(OCCCCCCCCCCCC(=O)OC)OC(C)(C)C)=CC(C)=C1C1=C(C)C=C(C)C=C1C KFYATKQGODTGCP-UHFFFAOYSA-N 0.000 description 1
- WVYBBOXJKXXXOY-UHFFFAOYSA-N methyl 12-hydroxydodecanoate Chemical compound COC(=O)CCCCCCCCCCCO WVYBBOXJKXXXOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- MVAOEXBRERPGIT-UHFFFAOYSA-N octamine Chemical compound N.N.N.N.N.N.N.N MVAOEXBRERPGIT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 230000005414 paramagnetic center Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- ZNMQQKJEWXWDAY-UHFFFAOYSA-N tert-butyl 2-[2,5-dimethyl-4-(2,4,6-trimethylphenyl)phenoxy]acetate Chemical compound CC1=CC(C)=CC(C)=C1C1=CC(C)=C(OCC(=O)OC(C)(C)C)C=C1C ZNMQQKJEWXWDAY-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
Definitions
- New cascade polymer complexes processes for their preparation and pharmaceutical compositions containing them
- the invention relates to the subject-matter characterized in the claims, that is to say novel cascade-polymer complexes, agents containing these compounds, the use of the complexes in diagnostics, and processes for the preparation of these compounds and agents.
- the currently used contrast media for the modern magnetic resonance imaging (MRI or NMR) [eg Magnevist ® , or ProHance ® ] are distributed throughout the extracellular space of the body (intravascular space and interstitium). This distribution space comprises about 20% of the body volume.
- Extracellular MRI contrast agents have been clinically used successfully in the diagnosis of cerebral and spinal disease processes, as this results in a very special situation with regard to the regional distribution space.
- extracellular contrast agents in healthy tissue can not leave the intravasal space due to the blood-brain barrier.
- regions with increased blood vessel permeability (permeability) for these extracellular contrast agents develop within the brain (Schmiedl et al., MRI of blood brain barrier permeability in astrocytic gliomas: application of small and large molecular weight contrast media, Magn. Reson. Med. 22: 288, 1991).
- a contrast agent would be desirable, which is distributed exclusively in the vascular space (vessel space).
- vascular space vascular space
- a blood-pool agent should make it possible, with the help of magnetic resonance imaging, to delineate well-perfused tissue from poorly perfused tissue and thus to diagnose ischaemia.
- infarcted tissue could be differentiated from the surrounding healthy or ischemic tissue due to its anemia when using a vasal contrast agent. This is of particular importance when e.g. It's about distinguishing a heart attack from ischemia.
- NMR contrast agents that can mark the vascular space (blood-pool-agent). These compounds should be characterized by good tolerability and high efficacy (high increase in signal intensity in MRI).
- the approach to solve at least part of these problems by using complexing agents bound to macro or biomolecules has been very limited.
- Macromolecules may generally be useful as contrast agents for angiography.
- Albumin-GdDTPA Radiology 1987; 162: 205
- 24 hours after intravenous injection in the rat shows an accumulation in the liver tissue, which accounts for almost 30% of the dose.
- only 20% of the dose is eliminated in 24 hours.
- the macromolecule polylysine-GdDTPA (European Patent Application, Publication No. 0 233 619) also proved suitable as a blood-pool agent. However, due to its production, this compound consists of a mixture of molecules of different sizes. In excretion experiments in rats, it was shown that this macromolecule is excreted unchanged by glomerular filtration through the kidney. However, due to its synthesis, polylysine-GdDTPA can also contain macromolecules that are so large that they can not pass through the kidney's capillaries during glomerular filtration and thus remain in the body.
- the disadvantage of these compounds is that they usually only carry about 5% of the signal-enhancing paramagnetic cation.
- the polymers described in European Patent Application No. 0 430 863 already represent a step towards blood pool agents, since they no longer have the size and molecular mass heterogeneity characteristic of the aforementioned polymers. However, they still leave desires open for prolonged retention in the blood, complete excretion, tolerability and / or efficacy.
- the cascade polymer complexes according to the invention can be described by the general formula I.
- R for an HSA-binding unit
- X and Y independently of one another for a direct bond or a cascade reproduction unit of the reproduction multiplicity x or y
- Z and W independently of one another for a direct bond or a cascade reproduction unit of the reproduction multiplicity z or w
- K for the rest of a complexing agent
- a for the numbers 2 to 12
- x, y, z and w are independent of the numbers 1 to 4, with the proviso that exactly one multiplicity of the base multiplicity a of the cascade core A represents exactly one binding site to L, and with the
- the cascade polymer complexes in the complexing agent residues K contain a total of at least 4 ions of an element of atomic number 20 to 29, 39, 42 to 44 or 57 to 83 and optionally cations of inorganic and / or organic bases, amino acids or amino acid amides include.
- Suitable cascade core A are: nitrogen atom,
- Q 1 is a hydrogen atom or Q 2 and Q 2 are a direct bond
- M 1 , M 2 , M 3 , M 4 independently represent a direct bond, a
- Oxygen atoms is interrupted and / or optionally with
- R 0 is a branched or unbranched Ci-Cjo-alkyl radical, a nitro, amino, carboxylic acid group or for
- the number of Q 2 contained in the above-described examples for the cascade core A represents the base multiplicity a.
- the reproduction units X, Y, Z and W contain -NQ 1 Q 2 groups, in which Q 1 is a hydrogen atom or Q 2 and Q 2 is a direct bond.
- the number of Q 2 contained in the respective reproduction unit (eg X) corresponds to the reproduction multiplicity. plicity of this unit (eg x in the case of X).
- the product of the multiplicities (al) -xyzw indicates the number of complexing agent residues K bound in the cascade polymer.
- the polymers of the invention contain at least 4 and at most 64 residues K in the molecule, each of which can bind one to a maximum of three (in the case of divalent ions), preferably an ion, of an element of the abovementioned atomic numbers.
- the cascade polymer complexes according to the invention have a maximum of 10 generations (ie more than only one of the reproduction units X, Y and Z in the molecule can be present), but preferably 2 to 5 generations, wherein at least two of the reproduction units in the molecule differently are.
- M 1 , M 2 , M 3 , M 4 independently represent a direct bond, -CH 2 -, -CO- or -CH 2 CO- group and R 0 represents a -CH 2 NU 1 U 2 -, CH 3 - or NO 2 group stands.
- cascade starters A are listed, for example:
- A is selected from:
- cascade core A and thus the separation of cascade core and first reproduction unit or linker can be chosen purely formal and thus independent of the actual synthetic structure of the desired cascade polymer complexes.
- the cascade reproduction units X, Y, Z and W are independent of each other
- Q 1 is hydrogen or Q 2 ,
- U 3 is a C 1-10 -alkylene chain which is optionally interrupted by 1 to 10 oxygen atoms and / or 1 to 2 -N (CO) q -R 2 -, 1 to 2 phenylene and / or 1 to 2 phenyleneoxy radicals and / / or optionally substituted by 1 to 2 oxo, thioxo, carboxy, C ⁇ - alkylcarboxy, Ci-C5-alkoxy, hydroxy, Ci-C 5 -alkyl groups, where q is the numbers 0 or 1 and
- R 2 represents a hydrogen atom, a methyl or an ethyl radical which is optionally substituted by 1 - 2 hydroxy or 1 carboxy group (s),
- B represents a hydrogen atom or the group
- Preferred cascade reproduction units X, Y, Z and W are those in which in the above-mentioned general formulas the radical U 3 is a direct bond, -CO-, -COCH 2 OCH 2 CO-, -COCH 2 -, -CH 2 CH 2 -, -CONHC 6 H 4 -, -COCH 2 CH 2 CO-, -COCH 2 -CH 2 CH 2 CO-, or -COCH 2 CH 2 CH 2 CH 2 CO-,
- the complexing agent residues K are described by the general formulas IA, IB and IC:
- n and m each represent the numbers 0, 1, 2, 3 or 4 and wherein the sum of n and m is not greater than 4,
- R 1 is independently of one another a hydrogen atom or a metal ion equivalent of atomic numbers 20-29, 39, 42-44 or 57-83,
- R 2 is a hydrogen atom, a methyl or an ethyl radical which is optionally substituted by 1 - 2 hydroxy or 1 carboxy group (s),
- R 4 iso-propyl, cyclohexyl, a straight-chain, branched, saturated or unsaturated C 1 -C 30 -alkyl chain which is optionally interrupted by 1-10 oxygen atoms, 1 phenylene, 1 phenyleneoxy groups and / or optionally by 1-5 hydroxy, 1 to 3 carboxy, 1 phenyl group (s) is substituted,
- R 5 is a hydrogen atom or R 4 ,
- U 6 is an optionally 1-5 imino, 1 to 3 phenylene, 1 to 3
- T is a -CO- ⁇ , -NHCO- ⁇ or -NHCS- ⁇ group
- Examples of U 6 include the following groups:
- the central ion of the complex salt must be paramagnetic.
- Suitable ions are, for example, the chromium (III), iron (II), cobalt (II), nickel ( II) - 5 copper (II), praseodymium (III), neodymium (III), samarium (III) and ytterbium (III) ions.
- the function of the structure L is to connect the two functional units R and A with each other.
- L can stand for a direct bond or a linker.
- the term linker for the purposes of this invention includes any chemical structure which is covalently bound to the HS A-bonding moiety R on one side and to the nitrogen-containing cascade core A on the other side, thus linking R to A.
- the meaning of the term linker is functionally defined and includes a large number of different chemical compounds. The skilled artisan can synthesize, on the basis of his knowledge, without undue burden, a large number of different linker structures which fulfill the function of the compound of R with A according to the invention. The skilled person only needs to carry out routine experiments.
- Preferred linker structures L include a direct bond, straight or branched, saturated or unsaturated carbon chains of one to 30 carbon atoms, which may be interrupted and / or substituted.
- the carbon chains of the linker are interrupted, they are preferably interrupted by one or more cyclic or heterocyclic carbon groups of from 3 to 8 carbon atoms or by one or more oxygen, nitrogen, sulfur and / or phosphorus atoms, optionally containing even further atoms, e.g. Hydrogen or oxygen, or groups may have bound.
- Linkers for the purposes of this invention may also include one or more amino acids.
- L is selected from: a direct bond
- the linkers L are oriented as indicated below:
- R is -CO-NH-CH 2 -CH 2 -A
- R is -O-CH 2 -CO-NH-aryl-C ⁇ C-aryl-CO-A.
- the compounds of formula I according to the invention include an HSA-binding moiety R, which is a chemical structure that binds to the protein human serum albumin (HSA) and has a direct binding to L.
- HSA-binding moiety R which is a chemical structure that binds to the protein human serum albumin (HSA) and has a direct binding to L.
- R has a molecular weight not greater than 2,000 Da.
- R has at least one specific binding affinity to HSA, the inhibition constant Ki being less than or equal to 50 ⁇ M, measured according to the method described in example 3 from US patent application with publication number US 2004/0254119 (West et al., US Application Number US 10 / 487,025).
- R has a Ki of less than or equal to 15 ⁇ M.
- Suitable HSA-binding groups R are given by way of example:
- the cascade polymer complexes according to the invention contain at least 4 ions of an element of the abovementioned atomic number.
- Preferred compounds of the formula I contain at least 8 ions of an element of the abovementioned atomic number.
- the remaining acidic hydrogen atoms may optionally be wholly or partly replaced by cations of inorganic and / or organic bases, amino acids or amino acid amides.
- Suitable inorganic cations are, for example, the lithium ion, the potassium ion, the calcium ion, the magnesium ion and in particular the sodium ion.
- Suitable cations of organic bases are, among others, those of primary, secondary or tertiary amines, such as ethanolamine, diethanolamine, morpholine, glucamine, N 5 N- dimethylglucamine and especially N-methylglucamine.
- Suitable cations of amino acids are, for example, those of lysine, arginine and ornithine and the amides of otherwise acidic or neutral amino acids.
- the compounds of the invention are characterized by a high blood concentration, especially at certain times. This is advantageous in choosing suitable imaging times and allows a more favorable signal-to-background ratio, especially at early and intermediate imaging times, as compared to compounds as described in European Patent EP 0 836 485.
- the compounds of the invention are particularly suitable for use as coronary angiography contrast agents and in NMR applications by means of higher magnetic field strengths such. B 1.5 or 3 Tesla.
- the compounds according to the invention which have a molecular weight of 5,000-60,000 Da, preferably 5,000-40,000 Da, have the desired properties described. They contain the large number of metal ions required for their use in the complex to be bound stably.
- the fields of application of the modern magnetic resonance imaging and computed tomography imaging methods are more specific: more specific diagnosis of malignant tumors, early therapy control in cytostatic, antiphlogistic or vasodilatory therapy, early detection of underperfused areas (eg in the myocardium), angiography in vascular diseases, and detection and diagnosis of (sterile or infectious) inflammation.
- the cascade polymer complexes according to the invention have surprising properties compared to known cascade polymer complexes, as described in the European patent EP 0 836 485. These surprising properties allow an even more flexible choice of imaging times and a more favorable signal-to-background ratio, especially at certain imaging times.
- Particularly surprising in comparison to the known cascade polymer complexes from EP 0 836 485 is, above all, that although the cascade polymer complexes according to the invention presented here have one polymer arm less than the known cascade complexes and are therefore rather smaller in comparison Thus, these should tend to extravasation, the novel cascade polymer complexes according to the invention even have a significantly improved residence time in the blood.
- the cascade polymer complexes according to the invention are also outstandingly suitable for (interstitial and i.v.) lymphography.
- the contrast agents according to the invention can be formulated as solutions isoosmolar to the blood and thereby reduce the osmotic load of the body, which is reflected in a reduced toxicity of the substance (higher toxic threshold). Lower doses and higher toxic thresholds lead to a significant increase in the safety of contrast agent applications in modern imaging techniques.
- the polymers according to the invention have -Complexes have a content of usually about 20% of the paramagnetic cation.
- the macromolecules of the invention produce a much higher signal amplification per molecule, which at the same time means that the dose necessary for magnetic resonance tomography is considerably smaller than the carbohydrate-based macro-molecular contrast medium.
- the cascade polymer complexes according to the invention are distinguished by improved precipitation behavior, higher activity, greater stability and / or better compatibility.
- a further advantage of the present invention is that now complexes with hydrophilic or lipophilic, macrocyclic or open-chain, low molecular weight or high molecular weight ligands have become accessible. This provides the opportunity to control the compatibility and pharmacokinetics of these polymer complexes by chemical substitution.
- R for an HSA-binding unit
- Base multiplicity a, X and Y independently of one another for a direct bond or a
- Cascade reproduction unit of the reproduction multiplicity x or y, Z and W independently of one another for a direct bond or a
- R 1 is independently of one another a hydrogen atom, a metal ion equivalent of atomic numbers 20-29, 39, 42-44 or 57-83 or an acid protecting group,
- R 2 is a hydrogen atom, a methyl or an ethyl radical which is optionally substituted by 1 - 2 hydroxy or 1 carboxy group (s), R3 "for one
- R 4 is iso-propyl, cyclohexyl, straight-chain, branched, saturated or unsaturated CPC3 0 alkyl, optionally substituted by 1 - interrupted 10 oxygen atoms, 1 phenylene, 1 Phenylenoxy phenomenon and / or optionally substituted by 1-5 hydroxy, 1 - 3 carboxy, 1 phenyl group (s) is substituted,
- R 5 is a hydrogen atom or R 4 ,
- U 6 is an optionally 1-5 imino, 1-3 phenylene, 1-3 phenyleneoxy, 1 -3 phenyleneimino, 1-5 amide, 1-2 hydrazide, 1-5 carbonyl, 1-5 Ethylenoxy-, 1 urea, 1-thiourea, 1 -2 carboxyalkylimino, 1 -2 ester groups, 1-10 oxygen, 1-5 sulfur and / or 1-5 nitrogen atom (s) containing and / or optionally by 1-5 hydroxy, 1-2 mercapto, 1-5 oxo, 1-5 thioxo, 1-3 carboxy, 1-5 carboxyalkyl, 1-5 ester and / or 1-3 amino (n) substituted straight-chain, branched, saturated or unsaturated C 1-10 -alkylene group, where the optionally-containing phenylene groups may be substituted by 1 to 2 carboxy, 1 to 2 sulfonic or 1 to 2 hydroxy groups,
- R 1 and R 2 independently of one another may each have the abovementioned meaning, with the proviso in that - if K 'is a complex - at least two (in the case of divalent metals) or three (in the case of trivalent metals) of the substituents R 1 represent a metal ion equivalent of the abovementioned elements and, if desired, further carboxyl groups in the form of their salts with inorganic and or organic bases, amino acids or amino acid amides,
- R 1 is independently of one another a hydrogen atom, a metal ion equivalent of atomic numbers 20-29, 39, 42-44 or 57-83 or an acid protecting group,
- R 2 is a hydrogen atom, a methyl or an ethyl radical which is optionally substituted by 1 - 2 hydroxy or 1 carboxy group (s),
- R 4 iso-propyl, cyclohexyl, a straight-chain, branched, saturated or unsaturated C j ⁇ Q alkyl chain, optionally substituted by 1-10 Oxygen atoms, 1 phenylene, 1 phenyleneoxy interrupted and / or optionally substituted by 1 - 5 hydroxy, 1 - 3 carboxy, 1 phenyl group (s), in particularly preferred embodiments, R 4 is selected from iso-propyl and cyclohexyl,
- U 6 is an optionally 1-5 irnino, 1-3 phenylene, 1-3 phenyleneoxy, 1 -3 phenyleneimino, 1-5 amide, 1-2 hydrazide, 1-5 carbonyl, 1-5 Ethylenoxy-, 1 urea, 1-thiourea, 1 -2 carboxyalkylimino, 1 -2 ester groups, 1-10 oxygen, 1-5 sulfur and / or 1-5 nitrogen atom (s) containing and / or optionally by 1-5 hydroxy, 1 to 2 mercapto, 1 to 5 oxo, 1 to 5 thioxo, 1 to 3 carboxy, 1 to 5 carboxyalkyl, 1 to 5 ester and / or 1 to 3 amino group (n) substituted straight chain, branched, saturated or unsaturated C j ⁇ o-alkylene group, wherein the optionally containing phenylene groups by 1-2 carboxy, 1-2 sulfone or 1-2 hydroxy groups may be substituted,
- An example of an activated carbonyl group C * O in the complexes or complexing agents K ' is anhydride, p-nitrophenyl ester, N-hydroxysuccinimide ester, pentafluorophenyl ester and acid chloride.
- the addition or acylation carried out to introduce the complexing agent units is carried out with substrates containing the desired substituent K (possibly bound to a leaving group) or from which the desired substituent is generated by the reaction.
- addition reactions include the reaction of isocyanates and isothiocyanates, the reaction of isocyanates preferably in aprotic solvents such as THF, dioxane, DMF, DMSO, methylene chloride at temperatures between 0 and 100 ° C, preferably between 0 and 50 0 C, optionally with addition of an organic base such as triethylamine, pyridine, lutidine, N-ethyldiisopropylamine, N-methylmorpholine, is performed.
- aprotic solvents such as THF, dioxane, DMF, DMSO, methylene chloride at temperatures between 0 and 100 ° C, preferably between 0 and 50 0 C
- an organic base such as triethylamine, pyridine, lutidine, N-ethyldiisopropylamine, N-methylmorpholine
- the reaction with isothiocyanates is usually in solvents such as water or lower alcohols such as methanol, ethanol, isopropanol or mixtures thereof, DMF or mixtures of DMF and water at temperatures between 0 and 100 ° C, preferably between 0 and 50 ° C. optionally with the addition of an organic or inorganic base such as triethylamine, pyridine, lutidine, N-ethyldiisopropylamine, N-methylmorpholine or alkaline earth, alkali metal hydroxides such as lithium, sodium, potassium, calcium hydroxide or their carbonates such as magnesium carbonate performed.
- solvents such as water or lower alcohols such as methanol, ethanol, isopropanol or mixtures thereof, DMF or mixtures of DMF and water at temperatures between 0 and 100 ° C, preferably between 0 and 50 ° C.
- an organic or inorganic base such as triethylamine, pyridine, lutidine, N-e
- acylation reactions the reaction of free carboxylic acids according to methods known to the person skilled in the art [e.g. J.P. Greenstein, M. Winitz, Chemistry of the Amino Acids, John Wiley & Sons, N.Y. (1961), pp. 943-945].
- carboxylic acid group into an activated form, such as, for example, before the acylation reaction.
- Anhydride, active ester or acid chloride e.g. E. Gross, J. Meienhofer, The Peptides, Academic Press, N.Y. (1979), Vol. 1, pp. 65-314; N.F. Albertson, Org. React. 12, 157 (1962)].
- R 1 is an acid protecting group, lower alkyl, aryl and aralkyl groups, for example the methyl, ethyl, propyl, butyl, phenyl, benzyl, diphenylmethyl, triphenylmethyl, bis- (p-nitrophenyl) -methyl distr, as well as trialkylsilyl groups in question.
- the optionally desired cleavage of the protective groups is carried out by the methods known to those skilled in the art, for example by hydrolysis, hydrogenolysis, alkaline saponification of the esters with alkali in aqueous-alcoholic solution at temperatures of 0 ° C to 50 0 C or in the case of tert-butyl esters Help of trifluoroacetic acid.
- Optionally incomplete acylated with ligand or complex terminal amino groups may, if desired, be converted to amides or hemiamides.
- Examples include the reaction with acetic anhydride, succinic anhydride or diglycolic anhydride.
- the introduction of the desired metal ions takes place in the manner disclosed, for example, in German Patent Publication DE 34 01 052, by reacting the metal oxide or a metal salt (for example the nitrate, acetate, carbonate, chloride or sulfate) of the element of the atomic numbers 20 - 29, 42, 44, 57 - 83 in water and / or a lower alcohol (such as methanol, ethanol or isopropanol) is dissolved or suspended and reacted with the solution or suspension of the equivalent amount of the complexing ligand and then, if desired, existing acid Hydrogen atoms of the acid groups substituted by cations of inorganic and / or organic bases, amino acids or amino acid amides.
- a metal salt for example the nitrate, acetate, carbonate, chloride or sulfate
- a lower alcohol such as methanol, ethanol or isopropanol
- the introduction of the desired metal ions can be carried out both at the stage of the complexing agent I 1 A or I 1 B, ie before coupling to the cascade polymers, as well as after coupling of the unmetallated ligands I 1 A or I'B.
- the neutralization is carried out using inorganic bases (for example, hydroxides, carbonates or bicarbonates) of, for example, sodium, potassium, lithium, magnesium or calcium and / or organic bases such as, inter alia, primary, secondary and tertiary amines, such as ethanolamine, morpholine , Glucamine, N-methyl and N, N-dimethylglucamine, as well as basic amino acids, such as lysine, arginine and ornithine, or amides of originally neutral or acidic amino acids, such as hippuric acid, glycine acetamide.
- inorganic bases for example, hydroxides, carbonates or bicarbonates
- inorganic bases for example, hydroxides, carbonates or bicarbonates
- organic bases such as, inter alia, primary, secondary and tertiary amines, such as ethanolamine, morpholine , Glucamine, N-methyl and N, N-dimethylglucamine, as well as basic amino acids, such as
- the neutral complex compounds it is possible to add, for example, to the acidic complex salts in aqueous solution or suspension so much of the desired bases that the neutral point is reached.
- the resulting solution can then be concentrated to dryness in vacuo.
- water-miscible solvents such as lower alcohols (methanol, ethanol, isopropanol and others), lower ketones (acetone and others), polar ethers (tetrahydrofuran, dioxane, 1, 2 -Dimethoxyethane and others) to precipitate and so easy to isolate and easy to clean crystals. It has proven to be particularly advantageous to add the desired base to the reaction mixture already during the complex formation and thereby to save a process step.
- acidic complex compounds contain several free acidic groups, it is often appropriate to prepare neutral mixed salts containing both inorganic and organic cations as counterions.
- the order of base addition can also be reversed.
- cascade core A and reproduction units or the connection to the linker L is purely formal. It may be synthetically advantageous not to use the formal cascade starter A (H) a , but introduces the by definition cascade core nitrogen atoms together with the first generation.
- Suitable amine protecting groups are the benzyloxycarbonyl, tertiary-butoxycarbonyl, trifluoroacetyl, fluorenylmethoxycarbonyl, benzyl and formyl groups known to the person skilled in the art [Th. W. Greene, PGM Wuts, Protective Groups in Organic Syntheses, 2nd Ed, John Wiley and Sons (1991), pp. 309-385]. After cleavage of these protecting groups, which also takes place by literature methods, the next desired generation can be introduced into the molecule.
- N-benzyloxycarbonyl-glycine is commercially available at e.g. Bachern California
- the complexes and complexing agents of the general formula I 1 A and I 1 B are prepared by or analogously to the instructions described in the experimental section or by methods known from the literature, see, for example, European Patent Applications Nos. 0 512 661, 0430 863, 0 255 471 and 0 565 930.
- the preparation of compounds of the general formula I 1 A can be carried out, for example, by serving as a precursor of the functional group T 1 is a group T ", either in the meaning of a protected acid function, independently of the acid protecting groups R 1 'after the above Process in which the free acid function can be transferred, or in the meaning of a protected amine function deblocking by literature methods [Th.W. Greene, PGM Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons (1991), p 309-385] and can then be converted into the isocyanates or isothiocyanates [Methods of Org. Chemistry (Houben-Weyl), E 4, pp.
- Such compounds can be prepared by or analogously to the instructions described in the experimental part by monoalkylation of cyclic compounds with suitable ⁇ -halocarboxamides [in aprotic solvents, such as, for example, chloroform].
- the preparation of compounds of the general formula I 1 B can be carried out, for example, by using a protected acid function as precursor of the activated carboxyl group C * O, which is converted into the free acid function independently of the acid protecting groups R 1 'according to the abovementioned processes and can be activated by the methods described above, the literature.
- Such compounds can be prepared according to or analogously to the instructions described in the experimental part or, for example, in that an amino acid derivative of the general formula II
- R 5 ' has the meaning given for R 5 , wherein optionally present in R 5 hydroxy or carboxy groups are optionally present in protected form and
- V 1 is a straight-chain or branched C 1 -C 6 -alkyl group, a benzyl, trimethylsilyl, triisopropylsilyl, 2,2,2-trifluoroethoxy or 2,2,2-trichloroethoxy group, where V 1 is different from R 1 " , with an alkylating agent of general formula III
- Hal represents a halogen atom such as Cl, Br or I, but preferably Cl, is reacted [see also M.A. Williams, H. Rapoport, J. Org. Chem. 58, 1151 (1993)].
- Preferred amino acid derivatives are the esters of naturally occurring ⁇ -amino acids.
- the reaction of compound (II) with compound (III) is preferably carried out in a buffered alkylation reaction, wherein the buffer is an aqueous phosphate buffer solution.
- the reaction takes place at pH values of 7-9, but preferably at pH 8.
- the buffer concentration may be between 0.1-2.5 M, but preferably a 2 M phosphate buffer solution is used.
- the temperature of the alkylation may be between 0 and 50 ° C; the preferred temperature is room temperature.
- the reaction is carried out in a polar solvent, e.g. Acetonitrile, tetrahydrofuran, 1,4-dioxane or 1, 2-dimethoxyethane performed.
- a polar solvent e.g. Acetonitrile, tetrahydrofuran, 1,4-dioxane or 1, 2-dimethoxyethane performed.
- acetonitrile is used.
- the preparation of the pharmaceutical compositions according to the invention is likewise carried out in a manner known per se by suspending or dissolving the complex compounds according to the invention in aqueous medium, if appropriate with addition of the additives customary in galenicals, and then optionally sterilizing the suspension or solution.
- suitable additives are, for example, physiologically acceptable buffers (such as tromethamine), additions of complexing agents or weak complexes (such as diethylenetriaminepentaacetic acid or the corresponding Ca-cascade polymer complexes) or, if necessary, electrolytes such as sodium chloride or, if necessary - Antioxidants such as ascorbic acid.
- suspensions or solutions of the agents according to the invention in water or physiological saline solution are desired for enteral administration or for other purposes, they are mixed with one or more excipients customarily used in galenicals [for example methylene chloride].
- excipients customarily used in galenicals [for example methylene chloride].
- the invention therefore also relates to processes for the preparation of the complex compounds and their salts. As final security remains a purification of the isolated complex salt.
- compositions according to the invention preferably contain 1 ⁇ mol - 1.3 mol / l of the complex salt and are usually metered in amounts of 0.0001 - 5 mmol / kg. They are intended for enteral and parenteral administration.
- the complex compounds according to the invention are used for NMR diagnosis in the form of their complexes with the ions selected from the elements having atomic numbers 21-29, 39, 42, 44 and 57-83.
- compositions of the invention meet the diverse requirements for suitability as a contrast agent for magnetic resonance imaging.
- they are ideally suited to improve after oral or parenteral administration by increasing the signal intensity of the image obtained using the magnetic resonance imaging in its validity.
- they show the high potency necessary to burden the body with the least possible amounts of foreign matter and the good compatibility needed to maintain the noninvasive nature of the studies.
- the agents according to the invention have a significantly higher concentration in the blood at relevant imaging times than the compounds described in the prior art, for example in European Patent EP 0 836 485.
- compositions according to the invention make it possible to produce highly concentrated solutions, to keep the volume load of the circuit within reasonable limits and to compensate for the dilution by the body fluid, ie NMR diagnostic agents must be 100-100 times better water-soluble than for the NMR spectroscopy.
- the compositions of the invention not only have a high stability in vitro, but also a surprisingly high stability in vivo, so that a release or replacement of non-covalently bound in the complexes - in itself toxic - ions within the time, in the new contrast media are completely excreted, only very slowly.
- the agents according to the invention are dosed for use as NMR diagnostic agents in amounts of from 0.0001 to 5 mmol / kg, preferably from 0.005 to 0.5 mmol / kg. Details of the application are described, for example, in H.-J. Weinmann et al., Am. J. of Roentgenology 142, 619 (1984).
- organ-specific NMR diagnostic agents can be used, for example, for the detection of tumors and of myocardial infarction.
- the compounds of the invention are characterized by a high blood concentration, especially at certain times. This is advantageous in choosing suitable imaging times and allows a more favorable signal-to-background ratio, especially at early and intermediate imaging times, as compared to compounds as described in European Patent EP 0 836 485.
- the compounds according to the invention are particularly suitable for use as coronary angiographic contrast agents and their use in NMR diagnosis by means of higher Magnetic fields such as 1.5 or 3 Tesla, as offered by modern NMR devices.
- the complex compounds according to the invention can advantageously be used as susceptibility reagents and as shift reagents for in vivo NMR spectroscopy.
- the compounds according to the invention are also suitable for the differentiation of malignant and benign tumors in areas without a blood-brain barrier.
- the phosphoramidite thus prepared is dissolved with 0.50 g (2.17 mmol) of 12-hydroxy-dodecanoic acid methyl ester in dried glassware in 15 mL dichloromethane, treated at 0 ° C with 3 g of 4 A molecular sieve and 8.6 mL of a 3% solution of tetrazole in acetonitrile and stirred at 0 ° C. for 1 h and at RT for 3 h. Subsequently, 0.72 ml of 80% strength t-butyl hydroperoxide are added and the mixture is stirred at RT overnight. It is filtered off and the solution is concentrated.
- Washed citric acid solution washed neutral with water and dried over sodium sulfate.
- Example 10d 1.0 g (0.2 mmol) of the octa-DTPA described in Example 10d are dissolved in 20 ml of water, combined with 290 mg (0.8 mmol) of gadolinium oxide and stirred at 80 ° C. for 30 min. The solution is treated with activated carbon, filtered and the filtrate with an acetonitrile / water gradient of Lichroprep ® RP-18 chromatographed and the product fractions freeze-dried.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880002489A CN101657219A (zh) | 2007-01-18 | 2008-01-16 | 新型的级联聚合物络合物、它们的制备方法以及包含它们的药物组合物 |
CA002676313A CA2676313A1 (en) | 2007-01-18 | 2008-01-16 | Novel cascade polymer complexes, processes for their preparation and pharmaceutical compositions comprising them |
JP2009545868A JP2010516643A (ja) | 2007-01-18 | 2008-01-16 | 新規カスケードポリマー錯体類、それらの調製方法、及びそれらを含んで成る医薬組成物 |
EP08701131A EP2111236A2 (de) | 2007-01-18 | 2008-01-16 | Neue kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
KR1020097015081A KR20090110838A (ko) | 2007-01-18 | 2008-01-16 | 신규한 캐스케이드 중합체 착체, 그의 제조 방법, 및 그를 함유하는 제약 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007002726.7 | 2007-01-18 | ||
DE102007002726A DE102007002726A1 (de) | 2007-01-18 | 2007-01-18 | Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008087017A2 true WO2008087017A2 (de) | 2008-07-24 |
WO2008087017A3 WO2008087017A3 (de) | 2009-01-22 |
Family
ID=39560934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/000285 WO2008087017A2 (de) | 2007-01-18 | 2008-01-16 | Neue kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080213187A1 (de) |
EP (1) | EP2111236A2 (de) |
JP (1) | JP2010516643A (de) |
KR (1) | KR20090110838A (de) |
CN (1) | CN101657219A (de) |
CA (1) | CA2676313A1 (de) |
DE (1) | DE102007002726A1 (de) |
WO (1) | WO2008087017A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127715A1 (en) * | 2008-04-18 | 2009-10-22 | Ge Healthcare As | Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy |
US10137209B2 (en) | 2015-06-04 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Gadolinium chelate compounds for use in magnetic resonance imaging |
US11814369B2 (en) | 2016-11-28 | 2023-11-14 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
US11944690B2 (en) | 2018-11-23 | 2024-04-02 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012050A1 (en) * | 1989-04-07 | 1990-10-18 | Salutar, Inc. | Chelants |
EP0430863A2 (de) * | 1989-11-21 | 1991-06-05 | Schering Aktiengesellschaft | Kaskadenpolymer-gebundene Komplexbildner, deren Komplexe und Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
WO1993006868A1 (en) * | 1991-10-07 | 1993-04-15 | COCKBAIN, Jilian, Roderick, Michaelson | Dendrimeric polychelants |
WO1995024221A1 (en) * | 1986-08-18 | 1995-09-14 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
WO1996001655A1 (de) * | 1994-07-07 | 1996-01-25 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe und ihre verfahren |
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
WO1997002051A2 (de) * | 1995-07-04 | 1997-01-23 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
WO1997023245A1 (de) * | 1995-12-22 | 1997-07-03 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
EP1334727A2 (de) * | 2000-11-03 | 2003-08-13 | Centro De Ingenieria Genetica Y Biotecnologia (Cigb) | Methode, antigene strukturen zu erhalten, welche spezifische kreuzreaktivität verstärken(15.05.02) |
WO2006029150A2 (en) * | 2004-09-03 | 2006-03-16 | Alza Corporation | Endogenously-formed conjugate of albumin |
EP1704864A2 (de) * | 1999-06-09 | 2006-09-27 | KTB Tumorforschungs GmbH | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
WO2006125134A1 (en) * | 2005-05-19 | 2006-11-23 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
EP1757701A1 (de) * | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1203164A (en) | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
NL194579C (nl) | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
US4707352A (en) | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group |
CA1266344A (en) | 1986-02-14 | 1990-02-27 | Miki Kurami | High molecular compounds having amino groups, and their utilization |
DE3625417C2 (de) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
GB8801646D0 (en) | 1988-01-26 | 1988-02-24 | Nycomed As | Chemical compounds |
DE3806795A1 (de) | 1988-02-29 | 1989-09-07 | Schering Ag | Polymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
DE4115789A1 (de) | 1991-05-10 | 1992-11-12 | Schering Ag | Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
AU663572B2 (en) | 1992-03-27 | 1995-10-12 | Nihon Medi-Physics Co., Ltd. | Tetraazacyclododecane derivative and its use |
DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
DE19652386A1 (de) | 1996-12-04 | 1998-06-10 | Schering Ag | Verfahren zur Herstellung von Metallkomplexcarbonsäureamiden |
-
2007
- 2007-01-18 DE DE102007002726A patent/DE102007002726A1/de not_active Withdrawn
-
2008
- 2008-01-16 JP JP2009545868A patent/JP2010516643A/ja active Pending
- 2008-01-16 CA CA002676313A patent/CA2676313A1/en not_active Abandoned
- 2008-01-16 WO PCT/EP2008/000285 patent/WO2008087017A2/de active Application Filing
- 2008-01-16 EP EP08701131A patent/EP2111236A2/de not_active Withdrawn
- 2008-01-16 KR KR1020097015081A patent/KR20090110838A/ko not_active Application Discontinuation
- 2008-01-16 CN CN200880002489A patent/CN101657219A/zh active Pending
- 2008-01-17 US US12/015,769 patent/US20080213187A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995024221A1 (en) * | 1986-08-18 | 1995-09-14 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
EP0481526A1 (de) * | 1989-04-07 | 1992-04-22 | Nycomed Salutar, Inc. | Chelatbildner |
WO1990012050A1 (en) * | 1989-04-07 | 1990-10-18 | Salutar, Inc. | Chelants |
US20020068037A1 (en) * | 1989-11-21 | 2002-06-06 | Schering Ag | Cascade polymer bound complexing compounds, their complexes and conjugates, process for their production, and pharmaceutical agents containing them |
EP0430863A2 (de) * | 1989-11-21 | 1991-06-05 | Schering Aktiengesellschaft | Kaskadenpolymer-gebundene Komplexbildner, deren Komplexe und Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
US6193950B1 (en) * | 1989-11-21 | 2001-02-27 | Schering Ag | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them |
WO1993006868A1 (en) * | 1991-10-07 | 1993-04-15 | COCKBAIN, Jilian, Roderick, Michaelson | Dendrimeric polychelants |
WO1996001655A1 (de) * | 1994-07-07 | 1996-01-25 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe und ihre verfahren |
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
WO1997002051A2 (de) * | 1995-07-04 | 1997-01-23 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
WO1997023245A1 (de) * | 1995-12-22 | 1997-07-03 | Schering Aktiengesellschaft | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
EP1704864A2 (de) * | 1999-06-09 | 2006-09-27 | KTB Tumorforschungs GmbH | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
EP1757701A1 (de) * | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen |
EP1334727A2 (de) * | 2000-11-03 | 2003-08-13 | Centro De Ingenieria Genetica Y Biotecnologia (Cigb) | Methode, antigene strukturen zu erhalten, welche spezifische kreuzreaktivität verstärken(15.05.02) |
WO2006029150A2 (en) * | 2004-09-03 | 2006-03-16 | Alza Corporation | Endogenously-formed conjugate of albumin |
WO2006125134A1 (en) * | 2005-05-19 | 2006-11-23 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
Non-Patent Citations (8)
Title |
---|
DATABASE DISSERTATION ABSTRACTS [Online] TEJADA, FREDERICK RUBIO [D.CHEM.] ET AL: "Investigations on the relaxometric properties of the macromolecular conjugates of DOTA-4AmP derivatives" XP002502985 gefunden im STN accession no. 2004:2719 Database accession no. AAI3087130 & DISSERTATION ABSTRACTS INTERNATIONAL, Bd. 64, Nr. 4b, 2002, Seite 1739, * |
GABELLIERI ET AL: "Dendrimer-protein interactions studied by tryptophan room temperature phosphorescence" BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, Bd. 1764, Nr. 11, 9. November 2006 (2006-11-09), Seiten 1750-1756, XP005755372 ISSN: 1570-9639 * |
KAPP TIMO ET AL: "Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]pl atinum(II) : Synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding" JOURNAL OF MEDICINAL CHEMISTRY, Bd. 49, Nr. 3, 2006, Seiten 1182-1190, XP002502983 ISSN: 0022-2623 * |
KLAJNERT B ET AL: "Interactions between PAMAM dendrimers and bovine serum albumin" BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, Bd. 1648, Nr. 1-2, 30. Mai 2003 (2003-05-30), Seiten 115-126, XP004425348 ISSN: 1570-9639 * |
VERA ET AL: "A molecular receptor-binding contrast agent for magnetic resonance imaging of the liver" ACADEMIC RADIOLOGY, Bd. 2, Nr. 6, 1. Juni 1995 (1995-06-01), Seiten 497-506, XP005306563 ISSN: 1076-6332 * |
VLASOV, G. P. ET AL: "Starburst conjugates of proteins with carbon-chain polymers containing low molecular biologically active compounds: synthesis and immunogenicity" RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY (TRANSLATION OF BIOORGANICHESKAYA KHIMIYA), Bd. 29, Nr. 1, 2003, Seiten 33-43, XP002502984 ISSN: 1068-1620 * |
WIENER E C ET AL: "DENDRIMER-BASED METAL CHELATES: A NEW CLASS OF MAGNETIC RESONANCE IMAGING CONTRAST AGENTS" MAGNETIC RESONANCE IN MEDICINE, Bd. 31, Nr. 1, 1994, Seiten 1-08, XP000423671 ISSN: 0740-3194 * |
ZHUO ET AL: "Synthesis, relaxivity and biodistribution of novel magnetic resonance imaging (MRI) contrast agents: polylysine (Gd-DTPA/DOTA) with pendent galactose moieties as hepatocyte-targeting groups" CHINESE CHEMICAL LETTERS, Bd. 8, Nr. 2, 1997, Seiten 157-160, XP002083557 ISSN: 1001-8417 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127715A1 (en) * | 2008-04-18 | 2009-10-22 | Ge Healthcare As | Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy |
US10137209B2 (en) | 2015-06-04 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Gadolinium chelate compounds for use in magnetic resonance imaging |
US10722601B2 (en) | 2015-06-04 | 2020-07-28 | Bayer Pharma Aktiengesellschaft | Gadolinium chelate compounds for use in magnetic resonance imaging |
US11491245B2 (en) | 2015-06-04 | 2022-11-08 | Bayer Pharma Aktiengesellschaft | Gadolinium chelate compounds for use in magnetic resonance imaging |
US11814369B2 (en) | 2016-11-28 | 2023-11-14 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
US11944690B2 (en) | 2018-11-23 | 2024-04-02 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101657219A (zh) | 2010-02-24 |
US20080213187A1 (en) | 2008-09-04 |
CA2676313A1 (en) | 2008-07-24 |
EP2111236A2 (de) | 2009-10-28 |
KR20090110838A (ko) | 2009-10-22 |
DE102007002726A1 (de) | 2008-07-31 |
WO2008087017A3 (de) | 2009-01-22 |
JP2010516643A (ja) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0836485B1 (de) | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
EP0768898B1 (de) | Kaskaden-polymer-komplexe und ihre verfahren | |
EP0430863B1 (de) | Kaskadenpolymer-gebundene Komplexbildner, deren Komplexe und Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
DE4115789A1 (de) | Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
WO1999001161A1 (de) | Oligomere, perfluoralkylhaltige verbindungen, verfahren zu deren herstellung und ihre verwendung in der nmr-diagnostik | |
DE10307759B3 (de) | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel | |
EP0868202B1 (de) | Kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
WO2008087017A2 (de) | Neue kaskaden-polymer-komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel | |
EP1307237B1 (de) | Perfluoralkylhaltige komplexe mit polaren resten, verfahren zu deren herstellung und ihre verwendung | |
DE19808079A1 (de) | Hydroxyethylstärke-Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
EP0946526B1 (de) | Macrocyclische metallkomplexcarbonsäuren, ihre verwendung sowie verfahren zu ihrer herstellung | |
DE102007058220A1 (de) | Dimere macrocyclisch substituierte Benzolderivate | |
WO2005115997A1 (de) | Trimere makrocyclisch substituierte aminoisophthalsäure-halogen-benzolderivate | |
WO2008046463A1 (de) | Metallchelate mit perfluoriertem peg-rest, verfahren zu deren herstellung sowie deren verwendung | |
EP1037671B1 (de) | Polyrotaxane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880002489.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08701131 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008701131 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4460/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2676313 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009545868 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097015081 Country of ref document: KR |